Rheumatology International

, Volume 33, Issue 11, pp 2819–2826 | Cite as

A study on the association of autoantibodies, chemokine, and its receptor with disease activity in systemic lupus erythematosus in North Indian population

  • Leishangthem Bidyalaxmi Devi
  • Archana Bhatnagar
  • Ajay Wanchu
  • Aman Sharma
Original Article

Abstract

Systemic lupus erythematosus (SLE) is a chronic and complex autoimmune disease characterized by the production of autoantibodies against a spectrum of nuclear antigens. RANTES and its receptor CCR5 have been associated with the pathogenesis of SLE. The objective of this study is to analyze autoantibodies (DNA/RNA), allelic distribution of RANTES and the association of levels of RANTES and its receptor CCR5 in SLE patients in North Indian region. The RANTES-403 and RANTES-28 polymorphism in the promoter region of RANTES gene was studied in 80 patients and 80 healthy controls. The levels of chemokine RANTES, its receptor CCR5, anti-dsDNA, and anti-SSA antibodies levels were determined. Disease activity was assessed with the systemic lupus erythematosus disease activity index (SLEDAI) score. All the parameters were studied for statistical analysis by using t test (graph pad prism) and correlation by SPSS data. PCR–RFLP performed showed 28C/C and the 403G/G genotypes in both patients and controls, but no other genotypes such as 28C/G, 28G/G and 403A/G, 403A/A were found. Patients had higher levels of RANTES (1840.48 ± 739.42 vs. 835.44 ± 70.48 pg/ml; P < 0.0001) and its receptor CCR5 expression (26.49 ± 0.16 vs. 24.72 ± 3.02 %; P < 0.05) compared to controls. The levels of autoantibodies anti-dsDNA and anti-SSA were also higher in patients than controls. The patients showing elevated anti-dsDNA had negative correlation with SLEDAI score (P < 0.05) while borderline patients were not found to be correlated. In case of anti-Ro/anti-SSA antibody levels, the borderline patients showed a moderately significant negative correlation as compared to controls than patients with elevated autoantibody (P < 0.01). The levels of RANTES and CCR5 were also higher in case of patients than controls. But there was no significant correlation of RANTES and CCR5 with disease activity. We were unable to find an association of RANTES polymorphism with SLE in North Indian population in our sample. No significant difference in allele distribution of RANTES-28 and RANTES-403 in the sample of 160 individuals was detected. Of the two autoantibodies studied, anti-Ro/anti-SSA levels in borderline lupus patients appeared as an important parameter for monitoring/diagnosis of lupus patients.

Keywords

RANTES CCR5 Anti-dsDNA Anti-Ro/anti-SSA Systemic lupus erythematosus 

References

  1. 1.
    Wallace DJ, Hahn BJ (1997) The clinical presentation of systemic lupus erythematosus. In: Wallace DJ, Hahn BH (eds) Dubois’ lupus erythematosus, 5th edn. Williams & Wilkins, Baltimore, p 627Google Scholar
  2. 2.
    Dieker JW, van der Vlag J, Berden JH (2002) Triggers for anti-chromatin autoantibody production in SLE. Lupus 11(12):856–864PubMedCrossRefGoogle Scholar
  3. 3.
    Lindqvist AK, Steinsson K, Johanneson B, Kristjansdottir H, Arnasson A, Grondal G, Jonasson I, Magnusson V, Sturfelt G, Truedsson L, Svenungsson E, Lundberg I, Terwilliger JD, Gyllensten UB, Alarcon-Riquelme ME (2000) A susceptibility locus for human systemic lupus erythematosus (hSLE1) on chromosome 2q. J Autoimmun 14(2):169–178. doi:10.1006/jaut.1999.0357 PubMedCrossRefGoogle Scholar
  4. 4.
    Eriksson C, Eneslatt K, Ivanoff J, Rantapaa-Dahlqvist S, Sundqvist KG (2003) Abnormal expression of chemokine receptors on T-cells from patients with systemic lupus erythematosus. Lupus 12(10):766–774PubMedCrossRefGoogle Scholar
  5. 5.
    Tsukahara T, Makino Y, Fujii T, Ogawa M, Saisho H, Hamano Y, Ueda S, Akikusa B, Danoff TM (2002) Role of RANTES in the development of autoimmune tissue injuries in MRL-Fas lpr mice. Clin Immunol 103(1):89–97. doi:10.1006/clim.2001.5198 PubMedCrossRefGoogle Scholar
  6. 6.
    Kameyoshi Y, Dorschner A, Mallet AI, Christophers E, Schroder JM (1992) Cytokine RANTES released by thrombin-stimulated platelets is a potent attractant for human eosinophils. J Exp Med 176(2):587–592PubMedCrossRefGoogle Scholar
  7. 7.
    Vila LM, Molina MJ, Mayor AM, Cruz JJ, Rios-Olivares E, Rios Z (2007) Association of serum MIP-1alpha, MIP-1beta, and RANTES with clinical manifestations, disease activity, and damage accrual in systemic lupus erythematosus. Clin Rheumatol 26(5):718–722. doi:10.1007/s10067-006-0387-y PubMedCrossRefGoogle Scholar
  8. 8.
    Anders HJ, Vielhauer V, Kretzler M, Cohen CD, Segerer S, Luckow B, Weller L, Grone HJ, Schlondorff D (2001) Chemokine and chemokine receptor expression during initiation and resolution of immune complex glomerulonephritis. J Am Soc Nephrol 12(5):919–931PubMedGoogle Scholar
  9. 9.
    Tian S, Li J, Wang L, Liu T, Liu H, Cheng G, Liu D, Deng Y, Gou R, Wan Y, Jia J, Chen C (2007) Urinary levels of RANTES and M-CSF are predictors of lupus nephritis flare. Inflamm Res 56(7):304–310. doi:10.1007/s00011-007-6147-x PubMedCrossRefGoogle Scholar
  10. 10.
    Stasikowska O, Danilewicz M, Wagrowska-Danilewicz M (2007) The significant role of RANTES and CCR5 in progressive tubulointerstitial lesions in lupus nephropathy. Pol J Pathol 58(1):35–40PubMedGoogle Scholar
  11. 11.
    Lloyd CM, Dorf ME, Proudfoot A, Salant DJ, Gutierrez-Ramos JC (1997) Role of MCP-1 and RANTES in inflammation and progression to fibrosis during murine crescentic nephritis. J Leukoc Biol 62(5):676–680PubMedGoogle Scholar
  12. 12.
    Furuichi K, Wada T, Sakai N, Iwata Y, Yoshimoto K, Shimizu M, Kobayashi K, Takasawa K, Kida H, Takeda SI, Mukaida N, Matsushima K, Yokoyama H (2000) Distinct expression of CCR1 and CCR5 in glomerular and interstitial lesions of human glomerular diseases. Am J Nephrol 20(4):291–299. doi:13603 PubMedCrossRefGoogle Scholar
  13. 13.
    Nelson PJ, Kim HT, Manning WC, Goralski TJ, Krensky AM (1993) Genomic organization and transcriptional regulation of the RANTES chemokine gene. J Immunol 151(5):2601–2612PubMedGoogle Scholar
  14. 14.
    Liu H, Chao D, Nakayama EE, Taguchi H, Goto M, Xin X, Takamatsu JK, Saito H, Ishikawa Y, Akaza T, Juji T, Takebe Y, Ohishi T, Fukutake K, Maruyama Y, Yashiki S, Sonoda S, Nakamura T, Nagai Y, Iwamoto A, Shioda T (1999) Polymorphism in RANTES chemokine promoter affects HIV-1 disease progression. Proc Natl Acad Sci USA 96(8):4581–4585PubMedCrossRefGoogle Scholar
  15. 15.
    Ye DQ, Yang SG, Li XP, Hu YS, Yin J, Zhang GQ, Liu HH, Wang Q, Zhang KC, Dong MX, Zhang XJ (2005) Polymorphisms in the promoter region of RANTES in Han Chinese and their relationship with systemic lupus erythematosus. Arch Dermatol Res 297(3):108–113. doi:10.1007/s00403-005-0581-9 PubMedCrossRefGoogle Scholar
  16. 16.
    Hassan AB, Lundberg IE, Isenberg D, Wahren-Herlenius M (2002) Serial analysis of Ro/SSA and La/SSB antibody levels and correlation with clinical disease activity in patients with systemic lupus erythematosus. Scand J Rheumatol 31(3):133–139PubMedGoogle Scholar
  17. 17.
    Praprotnik S, Bozic B, Kveder T, Rozman B (1999) Fluctuation of anti-Ro/SS-A antibody levels in patients with systemic lupus erythematosus and Sjogren’s syndrome: a prospective study. Clin Exp Rheumatol 17(1):63–68PubMedGoogle Scholar
  18. 18.
    Franceschini F, Cavazzana I (2005) Anti-Ro/SSA and La/SSB antibodies. Autoimmunity 38(1):55–63. doi:10.1080/08916930400022954 PubMedCrossRefGoogle Scholar
  19. 19.
    Arbuckle MR, McClain MT, Rubertone MV, Scofield RH, Dennis GJ, James JA, Harley JB (2003) Development of autoantibodies before the clinical onset of systemic lupus erythematosus. N Engl J Med 349(16):1526–1533. doi:10.1056/NEJMoa021933 PubMedCrossRefGoogle Scholar
  20. 20.
    Ahlin E, Mathsson L, Eloranta ML, Jonsdottir T, Gunnarsson I, Ronnblom L, Ronnelid J (2012) Autoantibodies associated with RNA are more enriched than anti-dsDNA antibodies in circulating immune complexes in SLE. Lupus 21(6):586–595. doi:10.1177/0961203311434938 PubMedCrossRefGoogle Scholar
  21. 21.
    Yoshimi R, Ueda A, Ozato K, Ishigatsubo Y (2012) Clinical and pathological roles of Ro/SSA autoantibody system. Clin Dev Immunol 2012:606195. doi:10.1155/2012/606195 PubMedCrossRefGoogle Scholar
  22. 22.
    Lindop R, Arentz G, Thurgood LA, Reed JH, Jackson MW, Gordon TP (2012) Pathogenicity and proteomic signatures of autoantibodies to Ro and La. Immunol Cell Biol 90(3):304–309. doi:10.1038/icb.2011.108 PubMedCrossRefGoogle Scholar
  23. 23.
    Izmirly PM, Saxena A, Kim MY, Wang D, Sahl SK, Llanos C, Friedman D, Buyon JP (2011) Maternal and fetal factors associated with mortality and morbidity in a multi-racial/ethnic registry of anti-SSA/Ro-associated cardiac neonatal lupus. Circulation 124(18):1927–1935. doi:10.1161/circulationaha.111.033894 PubMedCrossRefGoogle Scholar
  24. 24.
    Gade-Andavolu R, Comings DE, MacMurray J, Vuthoori RK, Tourtellotte WW, Nagra RM, Cone LA (2004) RANTES: a genetic risk marker for multiple sclerosis. Mult Scler 10(5):536–539PubMedCrossRefGoogle Scholar
  25. 25.
    Ye D (2001) Dermatosis epidemiology. The People Health Publishing House, BeijingGoogle Scholar
  26. 26.
    Aguilar F, Nunez-Roldan A, Torres B, Wichmann I, Sanchez-Roman J, Gonzalez-Escribano MF (2003) Chemokine receptor CCR2/CCR5 polymorphism in Spanish patients with systemic lupus erythematosus. J Rheumatol 30(8):1770–1774PubMedGoogle Scholar
  27. 27.
    Magnusson V, Lindqvist AK, Castillejo-Lopez C, Kristjansdottir H, Steinsson K, Grondal G, Sturfelt G, Truedsson L, Svenungsson E, Lundberg I, Gunnarsson I, Bolstad AI, Haga HJ, Jonsson R, Klareskog L, Alcocer-Varela J, Alarcon-Segovia D, Terwilliger JD, Gyllensten UB, Alarcon-Riquelme ME (2000) Fine mapping of the SLEB2 locus involved in susceptibility to systemic lupus erythematosus. Genomics 70(3):307–314. doi:10.1006/geno.2000.6374 PubMedCrossRefGoogle Scholar
  28. 28.
    Akalin E, Murphy B (2001) Gene polymorphisms and transplantation. Curr Opin Immunol 13(5):572–576PubMedCrossRefGoogle Scholar
  29. 29.
    Kelley VR, Rovin BH (2003) Chemokines: therapeutic targets for autoimmune and inflammatory renal disease. Springer Semin Immunopathol 24(4):411–421. doi:10.1007/s00281-003-0124-4 PubMedCrossRefGoogle Scholar
  30. 30.
    Lian LH, Kee BP, Ng HL, Chua KH (2011) Lack of association between RANTES-28, SDF-1 gene polymorphisms and systemic lupus erythematosus in the Malaysian population. Genet Mol Res 10(4):2841–2850. doi:10.4238/2011.November.17.2 PubMedCrossRefGoogle Scholar
  31. 31.
    Xu WD, Peng H, Zhou M, Zhang M, Li BZ, Pan HF, Ye DQ (2013) Association of RANTES and MBL gene polymorphisms with systemic lupus erythematosus: a meta-analysis. Mol Biol Rep 40(2):941–948. doi:10.1007/s11033-012-2135-5 PubMedCrossRefGoogle Scholar
  32. 32.
    Wada T, Furuichi K, Segawa-Takaeda C, Shimizu M, Sakai N, Takeda SI, Takasawa K, Kida H, Kobayashi KI, Mukaida N, Ohmoto Y, Matsushima K, Yokoyama H (1999) MIP-1alpha and MCP-1 contribute to crescents and interstitial lesions in human crescentic glomerulonephritis. Kidney Int 56(3):995–1003. doi:10.1046/j.1523-1755.1999.00646.x PubMedCrossRefGoogle Scholar
  33. 33.
    Lu MM, Wang J, Pan HF, Chen GM, Li J, Cen H, Feng CC, Ye DQ (2012) Increased serum RANTES in patients with systemic lupus erythematosus. Rheumatol Int 32(5):1231–1233. doi:10.1007/s00296-010-1761-2 PubMedCrossRefGoogle Scholar
  34. 34.
    Shah D, Wanchu A, Bhatnagar A (2011) Interaction between oxidative stress and chemokines: possible pathogenic role in systemic lupus erythematosus and rheumatoid arthritis. Immunobiology 216(9):1010–1017. doi:10.1016/j.imbio.2011.04.001 PubMedCrossRefGoogle Scholar
  35. 35.
    Gao HCS, Burkly LC, Jarchun I, Banas B, Schlondorff D et al (2006) TNF-like weak inducer of apoptosis (TWEAK) stimulates human kidney cells to elaborate chemokines central to the pathogenesis of lupus nephritis. Paper presented at the 2006 annual scientific meetingGoogle Scholar
  36. 36.
    Al-Saleh J, el-Eissawy S (2006) The role of T helper cell subsets in pathogenesis of systemic lupus erythematosus and their relation to disease activity. Egypt J Immunol 13(2):41–48PubMedGoogle Scholar

Copyright information

© Springer-Verlag Berlin Heidelberg 2013

Authors and Affiliations

  • Leishangthem Bidyalaxmi Devi
    • 1
  • Archana Bhatnagar
    • 1
  • Ajay Wanchu
    • 2
  • Aman Sharma
    • 3
  1. 1.Department of Biochemistry, Basic Medical Sciences BlockPunjab UniversityChandigarhIndia
  2. 2.Division of Arthritis and Rheumatic Diseases-OP09Oregon Health and Science UniversityPortlandUSA
  3. 3.Department of Internal MedicinePostgraduate Institute of Medical Education and ResearchChandigarhIndia

Personalised recommendations